Immix Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the application of chimeric antigen receptor T cell (CAR T) therapy in light chain (AL) amyloidosis and other serious diseases. The company’s lead candidate, NXC 201, is an autologous CAR T construct that targets B cell maturation antigen (BCMA) and is being evaluated in the Phase 1b/2 NEXICART 2 trial in the United States and the Phase 1b/2a NEXICART 1 trial ex US. Immix Biopharma, Inc. aims to harness the immune system through innovative cell therapies to deliver widely accessible cures for AL amyloidosis and related conditions. Its strategy includes advancing NXC 201 in AL amyloidosis and exploring additional indications where CAR T is not yet an approved therapy. The N GENIUS platform, which comprises a purpose built cell therapy evidence capture engine, proprietary EXPAND technology, and an atomized novel binding scaffold generation engine, has produced NXC 201 and is intended to support future product candidates. The platform’s purpose built cell therapy evidence capture engine links internal and external data to accelerate therapy design, manufacture, and preclinical work, while the EXPAND technology improves cell expansion and the atomized novel binding scaffold generation engine optimizes antigen binding.
Immix Biopharma, Inc. has not generated any revenue from product sales, licensing agreements, or collaborations to date because it has no approved therapies on the market. The company finances its research and development activities primarily through equity capital raises and non-dilutive grant funding. In December 2025, it completed an underwritten public offering of 19,117,646 shares at $5.10 per share, raising gross proceeds of approximately $100.0 million, along with pre funded warrants for additional capacity. Earlier in September 2025, the company closed two private placements that issued an aggregate of 3,915,604 shares and warrants to purchase up to 2,936,709 shares at a combined price of $2.37, yielding about $9.3 million in gross proceeds. Furthermore, Immix Biopharma, Inc. has been awarded an $8 million grant from the California Institute for Regenerative Medicine, of which $6.2 million had been received as of March 20, 2026, to support the clinical development of NXC 201 for relapsed/refractory AL amyloidosis. The net proceeds from these financings are intended to fund ongoing clinical trials, manufacturing activities, and general corporate expenses, while the CIRM grant supports specific milestones tied to patient enrollment in the NEXICART 2 study.
Immix Biopharma, Inc. occupies a specialized niche within the biotechnology industry as one of the few developers of autologous CAR T therapies targeting relapsed/refractory AL amyloidosis, a condition that currently lacks any FDA approved treatment as of March 2026. The global amyloidosis treatment market was estimated at $5.80 billion in 2024 and is projected to reach $11.13 billion by 2033, reflecting a compound annual growth rate of 7.5% from 2025 to 2033 according to Grand View Research. Competitors in this space include larger pharmaceutical and biotechnology enterprises such as Abbvie, Caelum Biosciences (operating as Alexion/AstraZeneca), and Janssen/Johnson & Johnson, which are investigating alternative modalities like small molecule inhibitors and monoclonal antibodies. Immix Biopharma, Inc.’s competitive advantages derive from its N GENIUS platform, which enables high transduction efficiency, low tonic signaling, and anti exhaustion characteristics in NXC 201, potentially reducing manufacturing complexity and toxicity risks. Additionally, the company has secured regulatory distinctions that may accelerate development, including Breakthrough Therapy designation (January 2026), Regenerative Medicine Advanced Therapy designation, and Orphan Drug designations from both the FDA and the European Commission for AL amyloidosis. The absence of approved therapies creates a significant unmet medical need, which Immix Biopharma, Inc. aims to address with a potential best in class CAR T product that could capture a meaningful share of the growing amyloidosis market.
As Immix Biopharma, Inc. has no commercial product, its current customer base consists of patients with relapsed/refractory AL amyloidosis who are enrolled in its clinical trials, as well as the hospitals, cancer centers, and academic institutions that serve as trial sites for the NEXICART 1 and NEXICART 2 studies. Upon potential regulatory approval, the company anticipates selling NXC 201 to healthcare providers that treat AL amyloidosis, including specialty hematology clinics, transplant centers, and multidisciplinary amyloid treatment programs. No specific customer names are disclosed in the filing. The company also anticipates engaging with health insurance providers and specialty pharmacy networks to facilitate reimbursement and distribution of NXC 201 should it obtain marketing approval.